Hospital

Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies.

These interim trial results support the ongoing phase 3 ITHACA trial.

Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

Study results showed that Black women with breast cancer were more likely to die across all subtypes, with the disparity varying from 17% to 50% depending on subtype.

Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

Investigators found a significant association for febrile seizures, but not with epilepsy.

Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

These results indicate the combination’s long-term effectiveness in a population with limited treatment options.

The discontinuation comes after a review of the medication by the European Medicines Agency which found that “the total number of deaths was higher than anticipated.”

The approval marks the only FDA-approved stand-alone therapy for the treatment of Niemann-Pick disease type C (NPC).

The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.

The decision is based on positive results from the phase 3 LAURA trial.

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Long-term shedding of mutated variants could pose a concern for spread among the public.

Treatment is typically tailored to the individuals, with HCT being the only curative treatment bone marrow failure, but long-term outcomes are generally poorer due to toxicities.

Although psychotherapy is the cornerstone, nutritional education and pharmacotherapies can also help patients recover

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

Pharmacy students discuss a non-traditional learning assignment that used the social media platform, TikTok.

William Carroll, PharmD, network vice president of pharmacy at Hackensack Meridian Health, discusses his hopes for the new partnership.

Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.

Approved with 3 new indications, bimekizumab-bkzx is the first and only interleukin-17 inhibitor approved for these diseases.

Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.